Schedule 13G ownership disclosure

TRAVERE THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 89422G107

Event date: 2024-12-31

Filing-level shares
2,114,056.00
Percent of class
2.4%
  • Woodline Partners LP

    Shares: 2,114,056.00 · Class: 2.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902664-25-001022
Form type
SCHEDULE 13G/A
Filer
Travere Therapeutics, Inc.
CIK
CIK 1438533
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub